Ansbert Gadicke, M.D., is co-founder and Managing Director of MPM and Managing Director of the Oncology Impact Fund. Ansbert led the company-building effort of several of MPM’s most successful investments including Biomarin (BMRN), Idenix (acquired by Merck:MRK), Pharmasset (acquired by Gilead:GILD) and Radius (RDUS) – companies devoted to providing transformative therapies.
Prior to founding MPM, Ansbert was at The Boston Consulting Group. He received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University. At the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert is a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of the Massachusetts General Hospital.